Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/ajp.117.2.97 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antipsychotic medication non-adherence and its determinants among out-patients with schizophrenia.
Malawi Med J
January 2025
Nnamdi Azikiwe University Ringgold standard institution - Department of Mental Health, Nnewi Campus, Nnewi, Anambra, Nigeria.
Introduction: While antipsychotics are key requirement in acute and long-term management of schizophrenia, medication adherence remains a major unmet need in its care. This paper assessed the prevalence of oral antipsychotic non-adherence among outpatients with schizophrenia and its associated clinico-demographic factors.
Method: Three hundred and ten adult outpatients (18-64 years of age) were cross-sectionally interviewed after being diagnosed of schizophrenia using ICD-10 criteria, and the diagnosis confirmed with the Mini International Neuropsychiatric Interview (MINI).
Prevalence and Characteristics of Delusional Infestation in Individuals With Opiate Use Disorders Within One Health System: A Retrospective Cross-Sectional Study.
Cureus
December 2024
Department of Medicine, Tower Health Medical Group, Reading, USA.
Objective: The recent development of xylazine adulteration of the illicit opiate supply has been associated with necrotic extremity wounds of unclear pathogenesis. This study sought to understand the prevalence and characteristics of delusional infestation (DI) among patients with opiate use disorders who also carried a diagnosis of cellulitis.
Methods: A retrospective cross-sectional study was performed in one health system to identify patients with opiate use disorder and cellulitis over the past three years who also described symptoms of DI.
Prognostic impact of psychoeducation program completion on inpatients with schizophrenia: a pilot cohort study.
BMC Psychiatry
January 2025
Department of Psychiatry, Shin-Abuyama Hospital, Osaka Institute of Clinical Psychiatry, Takatsuki, 569-1041, Japan.
Background: Psychoeducation programs can reduce the risk of recurrence and readmission in patients with schizophrenia. However, almost all previous studies of program efficacy have included only patients completing the program, which may not be possible in all cases. The objective of this pilot cohort study was to compare the prognoses of inpatients with schizophrenia who did or did not complete a well-established institutional psychoeducation program.
View Article and Find Full Text PDFInternational perspective on social cognition in schizophrenia: current stage and the next steps.
Eur Psychiatry
January 2025
Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
In the last decades, research from cognitive science, clinical psychology, psychiatry, and social neuroscience has provided mounting evidence that several social cognitive abilities are impaired in people with schizophrenia and contribute to functional difficulties and poor clinical outcomes. Social dysfunction is a hallmark of the illness, and yet, social cognition is seldom assessed in clinical practice or targeted for treatment. In this article, 17 international experts, from three different continents and six countries with expertise in social cognition and social neuroscience in schizophrenia, convened several meetings to provide clinicians with a summary of the most recent international research on social cognition evaluation and treatment in schizophrenia, and to lay out primary recommendations and procedures that can be integrated into their practice.
View Article and Find Full Text PDFAssociations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study.
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!